logo conference-reports

Conference Reports

Educational funding by logo MSD Oncology

ESMO ASIA 2019 – First Chinese trastuzumab biosimilar achieves primary endpoint in a phase 3 study

HLX02 was compared with an EU-sourced trastuzumab biosimilar.